117 related articles for article (PubMed ID: 38785683)
1. Comparing prospectively assigned trial and real-world lung cancer patients.
Walker B; Ray HE; Shao P; D'Ambrosio C; White C; Walker MS
J Comp Eff Res; 2024 May; ():e230176. PubMed ID: 38785683
[No Abstract] [Full Text] [Related]
2. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Mhatre SK; Machado RJM; Ton TGN; Trinh H; Mazieres J; Rittmeyer A; Bretscher MT
Clin Pharmacol Ther; 2023 Dec; 114(6):1313-1322. PubMed ID: 37696652
[TBL] [Abstract][Full Text] [Related]
5. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
[No Abstract] [Full Text] [Related]
6. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
[TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
10. Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.
Sengupta S; Ntambwe I; Tan K; Liang Q; Paulucci D; Castellanos E; Fiore J; Lane S; Micsinai Balan M; Viraswami-Apanna K; Sethuraman V; Samant M; Tiwari R
Clin Pharmacol Ther; 2023 Apr; 113(4):867-877. PubMed ID: 36606735
[TBL] [Abstract][Full Text] [Related]
11. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Rugo HS; Dieras V; Cortes J; Patt D; Wildiers H; O'Shaughnessy J; Zamora E; Yardley DA; Carter GC; Sheffield KM; Li L; Andre VAM; Li XI; Frenzel M; Huang YJ; Dickler MN; Tolaney SM
Breast Cancer Res Treat; 2020 Nov; 184(1):161-172. PubMed ID: 32789591
[TBL] [Abstract][Full Text] [Related]
12. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN; Pal N; Trinh H; Mahrus S; Bretscher MT; Machado RJM; Sadetsky N; Chaudhary N; Lu MW; Riely GJ
Clin Cancer Res; 2022 Jul; 28(13):2844-2853. PubMed ID: 35511917
[TBL] [Abstract][Full Text] [Related]
13. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
[TBL] [Abstract][Full Text] [Related]
18. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
[TBL] [Abstract][Full Text] [Related]
19. Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India.
M SG; Mohapatra PR; Bhuniya S; Das Majumdar SK; Mishra P; Panigrahi MK; Bal SK; Datta A; Venkatachalam P; Chatterjee D
Cureus; 2022 Oct; 14(10):e30589. PubMed ID: 36420233
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Porte M; Vaudron A; Crequit P; Vaugier L; Chatellier T; Fronteau C; Raimbourg J; Goronflot T; Bennouna J; Pons-Tostivint E
Clin Lung Cancer; 2024 Mar; 25(2):e101-e111.e2. PubMed ID: 38072729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]